Alopecia – Pipeline Review, 2019

Alopecia is a type of chronic condition, in which hair follicles get damaged due to patient’s autoimmune response. Both the genders hold an equal risk of being affected by alopecia. There are certain health conditions, in which the immune system of body attacks on hair follicles, resulting in an unpredictable hair loss. According to an article published by National Alopecia Areata Foundation in 2018, an estimated 6.8 million of the U.S. population gets affected by alopecia each year. Some of the studies suggest that extreme stress causes alopecia, however, genetic defects are prominently responsible for suffering from alopecia.

At present, there is no cure for alopecia. However, certain drugs such as Minoxidil, Anthralin, SADBE, and DPCP with other medication can be used to regenerate hairs. These drugs can help to re-grow hairs but they are not able to prevent hair loss. Currently, photochemotherapy is one of the efficient options to avoid invasive procedures.  

Academic centers and research institutes have focused on studying and developing new treatment options for the Alopecia. For instance; ATI-50002, which is being studied by Aclaris Therapeutics, Inc., is currently in phase-2 clinical trials to validate its efficacy for the treatment of alopecia areata.

To know how our report can help streamline your business, Speak to Analyst

At present more than 60% of the pipeline candidates for alopecia are in the phase-2 and phase-3 stage. Majority of the studies have been sponsored by academic centers and research institutes.

Report Description

The report on ‘Alopecia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Alopecia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Alopecia.

The report on ‘Alopecia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Alopecia
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Alopecia
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary